tirzepatide press release Lilly's new drug Mounjaro (tirzepatide ) wins US FDA approval Eli Lilly is now offering
Description
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association
Tirzepatide received expanded indication approval for paediatric patients with type 2 diabetes aged ten and over in December 2025
Compounded Tirzepatide delivers the same dual GLP-1/GIP hormone action as Mounjaro and Zepbound two of the most effective weight loss medications ever studied
What if my levothyroxine dose needs to change after weight loss
They are not recommended during pregnancy or breastfeeding, and caution is advised in patients with history of pancreatitis or severe gastrointestinal disease
For most people, these symptoms improve as their body adjusts, but in some cases, they can be severe enough to cause dehydration or discomfort
